Study measure | Numerator/denominator |
---|---|
1. First month ART pharmacy refill rates for newly diagnosed HIV-positive pregnant women | \( \frac{\#\ \mathrm{of}\ \mathrm{newly}\ \mathrm{diagnosed}\ \mathrm{H}\mathrm{I}\mathrm{V}\hbox{-} \mathrm{positive}\ \mathrm{pregnant}\ \mathrm{women}}{\#\ \mathrm{of}\ \mathrm{newly}\ \mathrm{diagnosed}\ \mathrm{H}\mathrm{I}\mathrm{V}\hbox{-} \mathrm{positive}\ \mathrm{pregnant}\ \mathrm{women}\ \mathrm{that}\ \mathrm{refill}\ \mathrm{their}\ \mathrm{ART}\ \mathrm{prescription}\ \mathrm{within}\ 45\ \mathrm{days}\ \mathrm{of}\ \mathrm{diagnosis}} \) |
2. 90-day ART pharmacy refill rates for newly diagnosed HIV-positive pregnant women | \( \frac{\#\ \mathrm{of}\ \mathrm{newly}\ \mathrm{diagnosed}\ \mathrm{H}\mathrm{I}\mathrm{V}\hbox{-} \mathrm{positive}\ \mathrm{pregnant}\ \mathrm{women}}{\#\ \mathrm{of}\ \mathrm{newly}\ \mathrm{diagnosed}\ \mathrm{H}\mathrm{I}\mathrm{V}\hbox{-} \mathrm{positive}\ \mathrm{pregnant}\ \mathrm{women}\ \mathrm{that}\ \mathrm{routinely}\ \mathrm{refill}\ \mathrm{the}\mathrm{ir}\ \mathrm{ART}\ \mathrm{medications}\ \mathrm{during}\ \mathrm{the}\ 90\ \mathrm{days}\ \mathrm{after}\ \mathrm{the}\mathrm{ir}\ \mathrm{diagnosis}} \) |
3. The percentage of newly diagnosed HIV-positive pregnant women that initiate ART within 14Â days | \( \frac{\#\ \mathrm{of}\ \mathrm{newly}\ \mathrm{diagnosed}\ \mathrm{H}\mathrm{I}\mathrm{V}\hbox{-} \mathrm{positive}\ \mathrm{pregnant}\ \mathrm{women}}{\#\ \mathrm{of}\ \mathrm{newly}\ \mathrm{diagnosed}\ \mathrm{H}\mathrm{I}\mathrm{V}\hbox{-} \mathrm{positive}\ \mathrm{pregnant}\ \mathrm{women}\ \mathrm{that}\ \mathrm{initiate}\ \mathrm{ART}\ \mathrm{within}\ 14\ \mathrm{days}\ \mathrm{of}\ \mathrm{their}\ \mathrm{diagnosis}} \) |